Literature DB >> 10939283

IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress.

R S Grant1, H Naif, M Espinosa, V Kapoor.   

Abstract

In the central nervous system (CNS), astrocytes play an integral role in the maintenance of neuronal viability and function. Inflammation within the CNS increases the concentration of oxidative metabolites and, therefore, the potential for NAD depletion through increased poly-(ADP-ribose) polymerase (PARP) activity. However, the activity of indoleamine 2,3-dioxygenase (IDO), the rate limiting enzyme for de novo NAD synthesis, is also markedly increased in astrocytes during inflammation. This study investigated the role of IDO induction in the maintenance of intracellular NAD and its relationship to improved cell viability under conditions of increased oxidative stress in the human astroglioma cell line, HTB-138. Treatment with the pro-inflammatory cytokine IFN-gamma increased IDO activity in these cells. Intracellular NAD levels also increased significantly after treatment with IFN-gamma in the presence of a PARP inhibitor. Pretreatment of astroglial cells with IFN-gamma significantly moderated both the drop in intracellular NAD concentration and cell death following exposure to hydrogen peroxide. These results suggest that induction of IDO and subsequent de novo NAD synthesis may contribute to the maintenance of intracellular NAD levels and cell viability under conditions of increased oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10939283     DOI: 10.1179/135100000101535357

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  23 in total

Review 1.  Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.

Authors:  Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo
Journal:  J Psychiatr Res       Date:  2015-05-19       Impact factor: 4.791

2.  In Utero Exposure to Histological Chorioamnionitis Primes the Exometabolomic Profiles of Preterm CD4+ T Lymphocytes.

Authors:  Poojitha Matta; Stacy D Sherrod; Christina C Marasco; Daniel J Moore; John A McLean; Joern-Hendrik Weitkamp
Journal:  J Immunol       Date:  2017-09-25       Impact factor: 5.422

Review 3.  NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns.

Authors:  Hassina Massudi; Ross Grant; Gilles J Guillemin; Nady Braidy
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

Review 4.  The role of the kynurenine metabolism in major depression.

Authors:  Aye-Mu Myint; Markus J Schwarz; Norbert Müller
Journal:  J Neural Transm (Vienna)       Date:  2011-12-03       Impact factor: 3.575

Review 5.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 6.  IDO and TDO as a potential therapeutic target in different types of depression.

Authors:  Yanjie Qin; Nanxi Wang; Xinlin Zhang; Xuemei Han; Xuejia Zhai; Yongning Lu
Journal:  Metab Brain Dis       Date:  2018-07-16       Impact factor: 3.584

Review 7.  Neuropsychiatric disorders related to interferon and interleukins treatment.

Authors:  Aye Mu Myint; Markus J Schwarz; Harry W M Steinbusch; Brian E Leonard
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

8.  Kynurenine Relaxes Arteries of Normotensive Women and Those With Preeclampsia.

Authors:  Stephanie A Worton; Harry A T Pritchard; Susan L Greenwood; Mariam Alakrawi; Alexander E P Heazell; Mark Wareing; Adam Greenstein; Jenny E Myers
Journal:  Circ Res       Date:  2021-03-03       Impact factor: 17.367

9.  Effects of Kynurenine Pathway Inhibition on NAD Metabolism and Cell Viability in Human Primary Astrocytes and Neurons.

Authors:  Nady Braidy; Gilles J Guillemin; Ross Grant
Journal:  Int J Tryptophan Res       Date:  2011-05-08

10.  Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.

Authors:  Derek A Wainwright; Mahua Dey; Alan Chang; Maciej S Lesniak
Journal:  Front Immunol       Date:  2013-05-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.